Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
"Early shareholders leap in on the promise of a new biotech breakthrough then lose patience at the slow pace of product development. Just months before a breakout, a winning biotech could be trading at a low point simply because many impatient shareholders moved on."
I think this sums up celz presently. Key words in that portion of a biotech article published this August, "just months before a breakout". Think about where celz is compared to January, then March and then June/July. Now ask yourself, with what has transpired from the business progression, are we closer to a legitimate "breakout" now more than ever before?
Really, this pps is junk drawer for sure BUT, it is not a result of slowing progress on Caverstem roll-out or a result of them continuing loan shark loans. PR's and 8K's and website updates are showing us that they are rolling swiftly down the track to $$ generation and when they can legally show us that, in the 10Q for Q3, then it will make many people return who became impatient without daily "news". I thinks it's fair to say that the news people really want are revenue figures that reaffirm the Caverstem budding business thesis. If that is confirmed with force on the income statement, this WILL reset to a totally different pps level, for the better IMO.
Until then? Hold on for your dear lives if you're long and strong. They are going to try REAL hard to stir doubt and shake you out. With just 23 days away from the Q release they have an eternity in otc lifespan to play some very tough games. Don't be one of the casualties if you can help it!
All posts my opinions, not investment advice. Good luck and hang on!
CELZY HOLDING STRONG!
Here's a Great POST from a Solid LONG i saved (all credit to them, not me!):
Q3 is done. Think about revenue $ #s.
Aug-Sept we were hoping the summer run would continue on.
We were incorrect. As Gump said, "sh*t happens."
But we all knew that Oct-Dec is when CMTH would begin showing
all that we believed this company to be. Why?
Because sh*t takes time to develop. Especially when
commercializing globally.
Let's talk #s and $.
http://www.caverstem.com/find-a-doctor-2/
(Excluding Dr. Gershman)
8 new doctors signed up
12 new locations procedures being done (1 w/ 2 doctors)
12-13 machines purchased ($20k per)
Estimated initial 5 kits purchased per machine ($1600 per)
Q3 total = approximately $340k (@ least)
Q2 total = $4800
That's a BIG % revenue increase!!
Eager big investors are waiting for these kinds of #s to justify
major growth ahead for CMTH, and the big spike in pps will follow!
**Not including any procedures done. We know from JBizzle's solid
DD that Dr. Liu and Dr Gershman have already done multiple
procedures as of a few weeks ago. This means more potential kits
being purchased for new patients. Thus, potentially more Q3 revenue.
**THESE ARE DOMESTIC #s ONLY
Forward thinking:
-Caverstem International-
The start of Q4 will have Russia beginning procedures this month
as recently stated by CMTH.
(Perhaps maybe Q3 will show revenue from this contract? I'm not
sure, but an extra bonus this would be.)
Also, we know CMTH has been working to expand Caverstem throughout
Europe. From August 16th 8k:
We are also currently working with Dr. Alexander Buchmann with
Alto Uro in Bern Switzerland to establish the CaverStem™ program
in Switzerland, Germany and Austria.
In that same August 8k was this statement:
Implementation of our contract with Promo Med continues to move forward.
(Regarding contract with Russia)
Within only two months, CMTH will already begin procedures in Russia.
Not too dang shabby for all those thinking this was just fluff news.
So how long ya think before procedures begin in the other
European countries mentioned, and more? Like Italy for example?
I know the Q won't be out for approximately 4-6 wks or so.
I understand OTC impatience. If ya can stomach the bs you read,
and can handle the games while waiting, great things will follow
for all patient shareholders.
Think two steps ahead.
It's all happening...
"Exciting times coming from Caverstem."
$CELZ
All posts my opinions only. NOT INVESTMENT ADVICE! Do your own due diligence.
People have learned - NO $CELZ DILUTION - the lie has been exposed and we can be confident that M M's have been shaking so many of their shares.
So SAD.
ZERO dilution in ALL of September. NONE! And with the PR/8K about the 3 NEW Institutional Investors "Wrapping up existing debt", there shouldn't be ANY dilution for the month of October either. NONE!
Now that the truth has been made known, what happens now?? The FEAR of dilution just lost its bite. The CELZ mgmt is humming along and making incredible progress for such a small company.
This is how ACES fly: FAST, TIGHT, and ON TARGET.
IMHO, CELZ MGMT are ACES of their SPACES. Do not underestimate the impact of a small but highly effective team of people. Jeff Bezos started AM A ZOn from a hole in the wall. One man in a van if you will. He took on the biggest retailer in the world and has changed the rules of the game. Can CELZ do the same in the ED space? The spine repair space? The cancer wasting disease space?
$CELZ has a world renowned Urologist that Hollywood's elite have expressed on live television that, "this man saved my life." leading the medical team for training new doctors on the patented CaverStem procedure. Dr. Gershman has been verified to have been in Switzerland working with Dr. Buchmann. This is also supporting evidence from a recent 8K: "Dr. Alexander Buchmann with Alto Uro in Bern Switzerland to establish the CaverStem™ program in Switzerland, Germany and Austria. We are pleased with the opportunity to work with a highly regarded physician such as Dr. Buchmann to expand CaverStem™ in Europe."
THEY ARE EXPANDING IN EUROPE. This doesn't even account for the ProMed deal in Russia which begins procedures THIS MONTH. Also, check the CaverStem facebook page to see that the word is spreading in the INTERNATIONAL urology community. An Italian all-star urologist reached out requesting information on how to become a provider in Italy! Read the PR's and the 8K's and the 10Q's.
The narrative that is $CELZ is incredible and we are witnessing this story being written in real time as it unfolds before our very eyes.
Trust but verify. All the LONGs on this board have been working to verify every detail. So far, so great on that front. Try not to let the fear of unknowns shake when the facts track record has been stellar, IMHO, for this OTC reporting company.
RED OR GREEN DON'T MEAN A THING UNTIL FINS COME SWIMMING IN. HOLD ON TIGHT UNTIL NOVEMBER 14TH for the REVENUE WE FULLY EXPECT TO ARRIVE.
All posts my opinion only. NOT INVESTMENT ADVICE. Do your own due diligence and if you don't like what you learn, do NOT buy it!
GREAT 8K SHOWS INCREDIBLE PROGRESS
Pair that with the Russian medical team starting procedures this MONTH, RIGHT NOW and CaverStem kit production is about to go to warp speed if it hasn't already! Q3 & Q4 are going to be stellar proof of CELZ's revenue potential. Soon thereafter, the peer-study release and BOOM. HODL until January/Feb '19. Can't imagine what this looks like by then!
About the new 8K...Some may say this is toxic scary financing as usual. Well, that is definitely NOT the case if you read the 8k and exhibits very carefully. Regarding these new convertible notes, let's remember that the new investors have eliminated the risk of potentially hundreds of millions of shares being converted for a max of 5% of the OS (@1B that's 50M shares, MAX). So, in August there was the highly likely future potential dilution of hundreds of millions in diluted shares coming down the pike and now it's limited to probably less than 50M if converted at all? That's an amazing restructuring if you think about it. Someone came in and said, we'll take all the $700,000 in debt risk and in return, get less of the company for doing so compared to the other loan sharks. Wow. Do you think they expect good things? Yeah, they also agreed to warrant strike prices 8.8X higher than the loan sharks. Why? Because they expect the PPS to be much higher than 8.8cents in the future. I like their point of view!!
Couple other notable points: Some have said that CELZ is going bankrupt from the gawd awful financials. Well, not only did they get the gawd awful loan sharks served up as a platter of fish-n-chips, they now have Institutional Investors backing them with working capital and no expectations of bankruptcy by the parties. From the 8K "Solvency. The Company has no knowledge of any facts or circumstances which lead it to believe that it will file for reorganization or liquidation under the bankruptcy or reorganization laws of any jurisdiction within one year from the Closing Date." Nice! And they put it in writing for the doubters! No more "ongoing concern" blather.
Just the facts folks:
Regarding the new investors convertible notes, they are LIMITED in the number of convertible shares up to 4.99% of outstanding shares. So, they can't get more than 50M shares on say 1B OS. THERE IS A LIMIT! and it's not at 60% DISCOUNT to last 20 traded days! Only a 35% DISCOUNT. MUCH BETTER TERMS INDEED.
--------------------------------------------------------------------
Full LIMITATION provision from 8K filing here:
d) Holder’s Conversion Limitations. From and after the date that the Conversion Shares are of a class of equity of the borrower registered under Section 12(g) of the Exchange Act or the Company is subject to the reporting requirements of Section 13 or Section 15(d) of the Exchange Act, Borrower shall not effect any conversion of this Note, and a Holder shall not have the right to convert any portion of this Note, to the extent that after giving effect to the conversion set forth on the applicable Notice of Conversion, the Holder (together with the Holder’s Affiliates, and any Persons acting as a group together with the Holder or any of the Holder’s Affiliates) would beneficially own in excess of the Beneficial Ownership Limitation (as defined below). For purposes of the foregoing sentence, the number of shares of Common Stock beneficially owned by the Holder and its Affiliates shall include the number of shares of Common Stock issuable upon conversion of this Note with respect to which such determination is being made, but shall exclude the number of shares of Common Stock which are issuable upon (i) conversion of the remaining, unconverted principal amount of this Note beneficially owned by the Holder or any of its Affiliates and (ii) exercise or conversion of the unexercised or unconverted portion of any other securities of Borrower subject to a limitation on conversion or exercise analogous to the limitation contained herein (including, without limitation, any other Notes or the Warrants) beneficially owned by the Holder or any of its Affiliates. Except as set forth in the preceding sentence, for purposes of this Section 4(d), beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder. To the extent that the limitation contained in this Section 4(d) applies, the determination of whether this Note is convertible (in relation to other securities owned by the Holder together with any Affiliates) and of which principal amount of this Note is convertible shall be in the sole discretion of the Holder, and the submission of a Notice of Conversion shall be deemed to be the Holder’s determination of whether this Note may be converted (in relation to other securities owned by the Holder together with any Affiliates) and which principal amount of this Note is convertible, in each case subject to the Beneficial Ownership Limitation. To ensure compliance with this restriction, the Holder will be deemed to represent to Borrower each time it delivers a Notice of Conversion that such Notice of Conversion has not violated the restrictions set forth in this paragraph and Borrower shall have no obligation to verify or confirm the accuracy of such determination. In addition, a determination as to any group status as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder. For purposes of this Section 4(d), in determining the number of outstanding shares of Common Stock, the Holder may rely on the number of outstanding shares of Common Stock as stated in the most recent of the following: (i) Borrower’s most recent periodic or annual report filed with the Commission, as the case may be, (ii) a more recent public announcement by Borrower, or (iii) a more recent written notice by Borrower or Borrower’s transfer agent setting forth the number of shares of Common Stock outstanding. Upon the written or oral request of a Holder, Borrower shall within two Trading Days confirm orally and in writing to the Holder the number of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of Borrower, including this Note, by the Holder or its Affiliates since the date as of which such number of outstanding shares of Common Stock was reported. The “Beneficial Ownership Limitation” shall be 4.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock issuable upon conversion of this Note held by the Holder. The Holder may decrease the Beneficial Ownership Limitation at any time and the Holder, upon not less than 61 days’ prior notice to Borrower, may increase the Beneficial Ownership Limitation provisions of this Section 4(d), provided that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock upon conversion of this Note held by the Holder and the Beneficial Ownership Limitation provisions of this Section 4(d) shall continue to apply. Any such increase will not be effective until the 61st day after such notice is delivered to Borrower. The Beneficial Ownership Limitation provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section 4(d) to correct this paragraph (or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation contained herein or to make changes or supplements necessary or desirable to properly give effect to such limitation. The limitations contained in this paragraph shall apply to a successor holder of this Note.
All posts my opinions only. Not investment advice. Do your own due diligence.
What? NO DILUTION SINCE AUGUST!?!?
ZINGER. Jaw drop. Sooo, what's the bloodbath been caused by? Care to speculate anyone?
I am RED. Crimson Red.
But, I AM NOT AFRAID. I am not mad at CMTH management. They are doing a GREAT job IMHO. I added some yesterday and am now going to make some major adjustments so I can ADD MORE at these ridiculous prices. The majority of dilution happened in Q1 and Q2. It has not been in Q3. We just got the update that shows ZERO dilution since AUGUST. ZERO!!!!! MY THEORY: What changed in June/July was a LOT of new eyes found CELZ on the 7 cent run. And a ton of people liked what they saw and STAYED. And ADDED even as the PPS upward blitz ended. And in doing so, many have soaked up a ton of the float (myself incl'd). Now, IMO, there is little to play with and so gravity is stronger than drifting to new heights. My theory at this point. Just a theory. A 70-100X revenue increase WILL bring whales in who are watching. I know a few who are waiting to see the "proof" in the Income stmt. They don't care about the debt. They don't care about the OS or dilution. THEY CARE ABOUT THE REVENUE EARNED so they can project a fair value at a reasonable # of doctors once they get to mostly "full-stock", i.e. have signed all the doctors they want.
Keep this in mind during the tree shaking: RED OR GREEN DON'T MEAN A THING UNTIL FINS COME SWIMMING IN. I have reliably said this all along -- go look at my posts.
We didn't get the Q2 FINS to do the trick for dime time (i loaded heavy in the 4's on the hopes we'd get $$ reported), it was a super long shot and I knew the risk when I dove in. So it didn't pan out, that was 50/50. I'm not crying a river about my bad bet there and I don't blame MGMT. Q2's revenue miss did give us a glimmer of what is to come with the $20,000 license fee that only showed as pre-payment in cash flow stmt, not INCOME Stmt. Needed that to be on INCOME Stmt. Guess what? It will be on INCOME stmt for Q3 reporting along with the other 8 MD's who signed up. That Q2 morsel was all I needed to keep loading all through September. IT PAYS TO PAY ATTENTION to the details folks. Q3 FINS WILL HAVE REVENUE IMHO. I've made a very big bet on this, as have many others.
Until November 14th (reporting day for 10Q) this could be a total massacre by market forces. It's OTC! Just mentally prepare for it and know that a certain cement company went from sub-penny to 60 cents in nearly 48 hours. On pure nothingness. What will CELZ do when it shows REVENUE GOLD and the whales have a FEAST on this pathetic PPS
It all comes down to one thing:
Either CELZ is going to show revenue and they are continuing to commercialize OR they don't show any and they are not doing anything at all. If it's the former, as most LONGS believe, IMAGINE WHAT THE PPS will do when they show $100k's+ in revenue with nice Gross Profit Margin. This is what you've all been waiting for. If it's the latter, I will tip my hat to those who disagree and admit my delusional view was so terribly wrong. We'll know soon enough.
HODL in place if you can! Whether this gets gorged to a penny or not, I WILL NOT sell a single share. My faith in the management executing their plan has not been shaken one iota. The chart will later testify about what many of us have believed all along. No chicken and egg situation here!
All my opinion and NOT investment advice. Do your own Due Diligence and don't buy if you don't like!
GREAT 8K SHOWS CREDIBLE PROGRESS
The PPS today seems to validate that. No? Just wait for October when the Russian medical team gets going. CaverStem kit production is about to go to warp speed if it hasn't already! Q3 & Q4 are going to be stellar proof of CELZ's revenue potential. Pair that with the peer-study release and BOOM. HODL until January/Feb '19. Can't imagine what this looks like by then!
About the new 8K...Some may say this is toxic scary financing as usual. Well, that is definitely NOT the case if you read the 8k and exhibits very carefully. Regarding these new convertible notes, let's remember that the new investors have eliminated the risk of potentially hundreds of millions of shares being converted for a max of 5% of the OS (@1B that's 50M shares, MAX). So, in August there was the highly likely future potential dilution of hundreds of millions in diluted shares coming down the pike and now it's limited to probably less than 50M if converted at all? That's an amazing restructuring if you think about it. Someone came in and said, we'll take all the $700,000 in debt risk and in return, get less of the company for doing so compared to the other loan sharks. Wow. Do you think they expect good things? Yeah, they also agreed to warrant strike prices 8.8X higher than the loan sharks. Why? Because they expect the PPS to be much higher than 8.8cents in the future. I like their point of view!!
Couple other notable points: Some have said that CELZ is going bankrupt from the gawd awful financials. Well, not only did they get the gawd awful loan sharks served up as a platter of fish-n-chips, they now have Institutional Investors backing them with working capital and no expectations of bankruptcy by the parties. From the 8K "Solvency. The Company has no knowledge of any facts or circumstances which lead it to believe that it will file for reorganization or liquidation under the bankruptcy or reorganization laws of any jurisdiction within one year from the Closing Date." Nice! And they put it in writing for the doubters! No more "ongoing concern" blather.
Just the facts folks:
Regarding the new investors convertible notes, they are LIMITED in the number of convertible shares up to 4.99% of outstanding shares. So, they can't get more than 50M shares on say 1B OS. THERE IS A LIMIT! and it's not at 60% DISCOUNT to last 20 traded days! Only a 35% DISCOUNT. MUCH BETTER TERMS INDEED.
--------------------------------------------------------------------
Full LIMITATION provision from 8K filing here:
d) Holder’s Conversion Limitations. From and after the date that the Conversion Shares are of a class of equity of the borrower registered under Section 12(g) of the Exchange Act or the Company is subject to the reporting requirements of Section 13 or Section 15(d) of the Exchange Act, Borrower shall not effect any conversion of this Note, and a Holder shall not have the right to convert any portion of this Note, to the extent that after giving effect to the conversion set forth on the applicable Notice of Conversion, the Holder (together with the Holder’s Affiliates, and any Persons acting as a group together with the Holder or any of the Holder’s Affiliates) would beneficially own in excess of the Beneficial Ownership Limitation (as defined below). For purposes of the foregoing sentence, the number of shares of Common Stock beneficially owned by the Holder and its Affiliates shall include the number of shares of Common Stock issuable upon conversion of this Note with respect to which such determination is being made, but shall exclude the number of shares of Common Stock which are issuable upon (i) conversion of the remaining, unconverted principal amount of this Note beneficially owned by the Holder or any of its Affiliates and (ii) exercise or conversion of the unexercised or unconverted portion of any other securities of Borrower subject to a limitation on conversion or exercise analogous to the limitation contained herein (including, without limitation, any other Notes or the Warrants) beneficially owned by the Holder or any of its Affiliates. Except as set forth in the preceding sentence, for purposes of this Section 4(d), beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder. To the extent that the limitation contained in this Section 4(d) applies, the determination of whether this Note is convertible (in relation to other securities owned by the Holder together with any Affiliates) and of which principal amount of this Note is convertible shall be in the sole discretion of the Holder, and the submission of a Notice of Conversion shall be deemed to be the Holder’s determination of whether this Note may be converted (in relation to other securities owned by the Holder together with any Affiliates) and which principal amount of this Note is convertible, in each case subject to the Beneficial Ownership Limitation. To ensure compliance with this restriction, the Holder will be deemed to represent to Borrower each time it delivers a Notice of Conversion that such Notice of Conversion has not violated the restrictions set forth in this paragraph and Borrower shall have no obligation to verify or confirm the accuracy of such determination. In addition, a determination as to any group status as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder. For purposes of this Section 4(d), in determining the number of outstanding shares of Common Stock, the Holder may rely on the number of outstanding shares of Common Stock as stated in the most recent of the following: (i) Borrower’s most recent periodic or annual report filed with the Commission, as the case may be, (ii) a more recent public announcement by Borrower, or (iii) a more recent written notice by Borrower or Borrower’s transfer agent setting forth the number of shares of Common Stock outstanding. Upon the written or oral request of a Holder, Borrower shall within two Trading Days confirm orally and in writing to the Holder the number of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of Borrower, including this Note, by the Holder or its Affiliates since the date as of which such number of outstanding shares of Common Stock was reported. The “Beneficial Ownership Limitation” shall be 4.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock issuable upon conversion of this Note held by the Holder. The Holder may decrease the Beneficial Ownership Limitation at any time and the Holder, upon not less than 61 days’ prior notice to Borrower, may increase the Beneficial Ownership Limitation provisions of this Section 4(d), provided that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock upon conversion of this Note held by the Holder and the Beneficial Ownership Limitation provisions of this Section 4(d) shall continue to apply. Any such increase will not be effective until the 61st day after such notice is delivered to Borrower. The Beneficial Ownership Limitation provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section 4(d) to correct this paragraph (or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation contained herein or to make changes or supplements necessary or desirable to properly give effect to such limitation. The limitations contained in this paragraph shall apply to a successor holder of this Note.
All posts my opinions only. Not investment advice. Do your own due diligence.
What if CELZ future is really BRIGHT?
To all the voices that lament OS and the "dilution machine" I posit this question:
Would you have bought CELZ shares on January 3, 2018 when OS was 106M if you KNEW that the OS would swell to 787M shares today and the PPS would be 85% higher @ today's prices anyway? Well, would you? (I wish I had plunked $1M down then!)
How about in March, when there was no news to speak of, no clue if the company was actually going to stay in business (no Institutionals were interested then!) or whether they were going to sell any CaverStem licenses and the OS had swollen to ~250M in 1.5 months (OH NO! 2.35X! SUPER SCARY!!). Share price was sub-penny (~0.0025-0.004) and maybe it should of been. There was NO VISIBILITY with respect to seeing down their road of next steps. A ton had to go right between March and June for CELZ or they wouldn't be here now. Speaking of now, with over double the OS again (in 6 months...), the share price is PENNIES. Crazy, right? Who woulda thought this was possible. Certainly doesn't seem reasonable according to the gloomers. Well, it is possible because a few things have happened since March. For a full list, check out JB's DD that is stickied on this board, it's top notch. Here's super short version: They went to the AUA in May and it was GOOD. Then they signed some doctors! WOW. The business "idea" just turned into a "business". Then, they signed up 8 more in June/July. Then that whole "Russia" deal thing in July that we now know will be a kit sucking machine beginning in October (this year!). Then SWITZERLAND and Europe at large. Did I forget super cool and celebrity-like Lamborghini driving Italian Urologist wanting in on the action?
Maybe all this dilution chatter and gloom and doom is right. Maybe CELZ is just a toilet paper operation and ain't nothing good. Maybe Dr. Gershman really wasn't the doctor for Frank Sinatra Jr. and the Entertainment Tonight interview with them both was a sham. Maybe all the other top-shelf MD's are total cons and have been for 40+ years (some of them have been playing doctor a long time!) Maybe mgmt should get into the super non-competitive drone business or something so they can make "real" money. So many people were saying that some other drone biz was done with dilution and watch out for the rocket flight. Then, I saw that "apparently" there WAS dilution AGAIN. Doh! Man, isn't that OTC? One minute it's this, the next minute it's that. Who are we supposed to believe?!?! Ugh, it is so confusing some times.
What if, instead of believing all the negative chatter, one looked at CELZ's story unfolding and then looked at its stock behavior YTD, they would find a much different perspective would form. Not only is the commercialization (i.e. the actual roll-out of a business that has, until now, only been an idea on paper) of CaverStem happening before our very eyes but this CELZ team is getting the corporate structure reinforced with some Institutional Investors. None of that would be possible if there wasn't something really compelling underway. What do Institutional Investors showing up imply?
• That CELZ isn't knocking on death's door anymore. Their PR words say that the Institutionals are not only here to "wrap up the existing debt" but they are also here to provide the working capital needed to get all these patents commercialized. There goes the theory that CELZ isn't worth the hold because of the $800k in maturing debts (that # was tossed around on twitter...not accurate though).
• Conventional VALUE driven investors are buying into the CELZ story. They wouldn't want to provide working capital to a company whose story wasn't really good and the odds were favorable for not only survivable but SUCCESS. Guess what other companies attracted Institutional investors because of the really good story? T S L A among others.
• Many other things but those two are the big ones
[/color]
So, WHAT IF, OS gets to 1 BILLION? Is it possible that PPS gets to 25 cents ANYWAY? Well, if you reasonably look at what CELZ has done since January, the answer is pretty clear. Not only is "possible" doable, it appears to be down right probable. The Blue Pill company has an OS of 5.8 Billion and a share price of $43 per. Hmm. I wonder why it's OK for them and not for CELZ.
Do your own due diligence and realize that nothing is as it seems. There will be bad nuances that come with the good ones. That's life much less business. The key is to stay reasonable and look at the BIG PICTURE to gain the best point of view of what's going on around you.
When I look at CELZ, I like what I see.
All posts are my own opinions and they are NOT investment advice. Do your own due diligence!
Echoing the other guys here DocPrep...hang in there and sincere condolences to you and your family.
My one allowed post for today. Stay positive in the valley and climb onwards longs!
Not hardly! CELZy is SEXY!
Are you getting whip-lash from vacillating from negative to positive views? SMHLTR. The "market" isn't tired at all. Nothing is as it seems and that undoubtedly makes "intellectuals" get twitchy. The reality is that there is a tremendous shifting of sands happening beneath our very feet at this very moment. Nothing that has been trading the last two weeks is what any of us can accurately claim. I thought it was dilution plain and simple. And in some ways, it likely was BUT NOT FOR THE REASONS I THOUGHT. Now, with Institutional Investors apparently on the scene and likely have been for a few weeks, the foregone conclusions of all this "crazy" trading should be tossed out the window. There are WHALES of the most stable and forward minded kind making long-term working capital plans with CMTH. We won't have any idea what those terms are until the 8k cometh but it doesn't matter IMHO what the terms are. The rules of engagement have just taken a massive step toward CREDIBLE and LEGITIMATE. People lament the toxic notes and then shift to lament the Institutionals. Give me a freaking break. I am celebrating yesterday's news because it only re-affirms my thesis of CELZy getting more fit and sexy each passing day. I am confident that the sideways stuff going on as I type is not for the reasons any of us can speculate. There could be massive plans underway as respects "wrapping up existing debt" - think about those choice words for a second. Man does that sound good! In the very short interim (could be a couple weeks!) this may sit like a dead duck floating on the water. Why? The MM's have realized that they are about to get creamed and it won't be the good CaverStem kind. I suspect the institutionals were the ones soaking up the 3.4 cents shares last week. They could of totally made some deals with the toxic holders to get the debts cleared at a fixed rate and limited the downward damage. (Pure speculation on my part but it seems logical). We were all thinking it could test the 2's and others were ominously predicting sub-pennies were on tap. Does anyone think that is likely now? ANyone? Does anyone think INSTITUTIONAL INVESTORS want the PPS to go down vs. UP? We all know the toxic trash loaners don't give a dmn about the PPS and they had the incentive to drive the PPS DOWN. But now, oh but now, the new kid on the block has REAL cash at their disposal AND the motive to see PPS GO UP as they invest for the longer-term and with an intent to ADD VALUE. Again, the transition from toxic OTC funding to "regular bank loans" to the now-on-deck strategic investment partners bodes very very well for CELZ and the PPS at large. The new stakeholders will have more aligned interests (PPS GOING UP) than at any other time this year. How do you think that impacts things when the dust settles and the writing is clearly visible. None of that even taps the fact that institutional investors brings a critical layer and level of protection to the CELZ coming out party to fend off the big pharma trolls. So many fringe benefits that come from hook'n up with BIG boys.
Chicken Little is a fun kid movie but it has no place in the CELZ thread. We all get that uva is either bipolar or a bashr incognito. I for one am getting tired of the short attention span, incessant demands for getting insider info and narrow vision.
I don't care if she trades right side, left side, upside or bottomside in the next week or two; things are looking UP. October/Nov should be incredible!!!
My opinions only. Not investment advice. Do your own due diligence.
Nailed it Carlton!
If they get 20 MD's signed by EOY (close to half-way in July alone), kit revenue could easily be $200,000 PER MONTH if those doctors only use 10 kits per month (assuming $1K in kit margin) which is very conservative IMHO. That doesn't even factor the upfront $20k per doctor licensing fee or separation machine revenues.
If 20 docs use 30 kits a month, that's $600,000 per month potential.
When they get 100 doctors (maybe a year or more or less?) and those 100 MD's globally use 10 kits a month, that's $1,000,000 per MONTH in potential kit revenue. Add in $2M from licensing fees and ?$? from cell separation machine sales and we're talking real movement here.
1B OS (if it ever gets there) won't matter with all that $$ coming in.
If we trade at $0.0244 with near zero revenue, imagine what this will trade at with millions in revenue. Many Biotechs trade in the $$'s and they have zero revenue or proof of concept in sight. We have both!
GO $CELZ!
All posts my own opinions. Not investment advice.
Very wise and well reasoned angle 3King!
The sky isn't falling here...but the roller coaster will surely make many vomit and some fall off! This ain't for the weak but the reward doesn't normally go to them anyway. Let no one be delusional with what is at hand. The reality is that convertible note holders would prefer to convert than let CMTH pre-pay now that they have $$ coming in. Gulp, I said it. Now get over it and get real with the facts. It's a better deal for them, simple as that. The pre-pays option on the existing notes expire: Oct 3, 11 and 13th. Due to the gutter ball PPS as of late, the incentive is there to act now to get the best return for a note converter (more shares at the 60% discount). Another reason for the haste to convert is the ever imminent PR or 8K that provides positive news causing a run in this interim window (until Oct 13). While many cry about dilution being the end of it all, the simple fact is that although punitive, it is not terminal by any means, certainly not based on the history of CELZ. Even as the OS has bloated with dilution, the PPS has remained on an upward trajectory. There is no reason to expect that course of action to change now that doctors are clearly signing up and paying up.
Bottom line? Hang tight if you like what CELZ mgmt is doing or exit stage right and chase something else. I did notice someone talking about a different stock (immune based biotech) that did an RS and then, shortly thereafter, went UP dramatically. Hmm. Headscratcher. I thought all RS's were "awful". Maybe that's not the truth? That's all the proof anybody here needs to see that even if an RS happens to a stock, if the stock is a good one, it can be a net neutral or even a big catalyst UP. Most OTC RS's are ominous, I'll agree with that BUT, I would speculate that if (ZERO INDICATIONS THUS FAR) one happened for CELZ, it would be an exception like that other recent example.
FACTS:
CELZ is not bankrupt despite calls by many saying they are. Didn't they just hire a new top salesperson for the east coast? How did they do that if they are bankrupt?? They continue to operate and expand. They have a mild $65k per month burn rate (much less than many scientific research co's) and their CFO/COO is top-shelf if you just google Donald Dickerson and look up his LinkedIn page.
CELZ has tapped the ugly financing pools to pay for operations. It's a reality for MOST biotech startups. Those ugly terms are just part of the tapestry. HOWEVER, the tide began to change in June from ugly to much more reasonable. The last reported convertible note was issued on May 14th. They have secured two notes since then that were "regular" term notes with non-convertible terms and reasonable interest rates. How and why did this pivot occur? Simple. They started signing up doctors and getting handsome license fees UPFRONT. Never mind the kit sales that will be even more substantial as these top-class MD's start performing procedures all over the WORLD.
DESPITE the dilution and ugly terms of convertible notes, CELZ PPS has GONE UP this year.
December 2017: 106M Outstanding Shares and the share price was $0.0135
Yesterday's close 2018: 784M (last reported) but probably 825M now (just a guess) Outstanding Shares and PPS was what? $0.0305
That's right folks. Even with the scary swelling OS (678% increase), the PPS is UP 125.92% THIS YEAR. Anybody else find that impressive?
I, for one, would prefer they get all these notes completely converted this month (worst month for stocks historically anyway) and have a nice October bump up that is sustained into EOY with a good 10Q and study publishing. Can you imagine what this PPS will do when the Peer-Review Study is released by LABIOMED paired with revenue reports showing $100k's+ in MD sign ups? Gets me excited!
IF they purge the notes and they can support month-to-month from new MD's signing up + kit sales, it really won't matter if OS grows to 850M or 1B. If the convertible notes end and more reasonable borrowing prevails + revenue, this thing should POP.
AIMHO.
My sole allowed post. Good luck in the miserable waiting and don't despair too much, CELZ has bounced back many times already! Just look at the chart since January...
You lil dream weaver you!
Won't be long and the debates on this thread will only be about what shade of green CELZ closed up at each day.
Til then, Good Luck to Longs and HODL until the clouds clear!
MAJOR move UP is imminent This 104.76% "bounce" from .021 last week is NOTHING. Just you wait and see. By the next 10Q, this could easily run to 50 cent and beyond. With what's stirring TODAY, absolutely NO reason we can't be sitting at 25 - 30 cents by Sept 15th. How dare I? Look at the chart below. CELZ was UP 1,580% in six months with an increase of 517M in OS with little public commercial progress. And now? All-Star doctors from around the world are calling. 8-10 already signed and CaverStem Int'l was formed and doctors engaged. You do the logical math. Don't let BS about OS increases scare you from the brilliant facts shining on CELZ at this moment.
Rock solid IP portfolio.
THE ONLY PEER REVIEWED STEM CELL STUDY on THEIR PATENTED ED CURE coming soon.
Rock solid woody's from bone marrow stem cells vs. blubber.
Doctors from ALL OVER THE WORLD are reaching out trying to get a license. (think about their $$ ability to invest in CELZ too! Double dippin at it's finest.)
It is finally fall. Trading will be back in FULL swing and the timing with CaverStem's international debut is simply stellar. The stars have aligned and they've just created a new constellation named: C E L Z Y
Do YOU see it? Fortunate the ones who do!
It's all coming together and the MM's can't hold it back. They did a fine text-book job in July/Aug of beating this down BUT that was a coin flip of luck. If the May AUA had been one month earlier, the dive wouldn't of happened IMHO.
Stay LONG, HOLD STRONG and GO CELZ!!!!!!!!!!!
WANT CELZ FACTS? SEC NOTE 4 - DEBT (included in its entirety herein)
Look for all the red bolded text...that will show you the status of the payoffs and the status of the loans that remain. CELZ HAS PAID OFF MORE LOANS THAN WHAT REMAINS. READ FOR YOURSELF.
A few other comments regarding the "future" loans due at the very end of this 10Q Note 4: As of June 30, 2018, future loan maturities are as follows:
For the year ended December 31,
2018: $ 118,434
2019: $ 554,658
Total $ 673,092
Ask yourself, is it possible they could pre-pay any of these future loan maturities? The answer is: YES. Is it possible they already have? The answer is: YES. If PRO-MED (Russian contract deal) paid a $1M exclusive license fee (maybe more?), don't you think they might just pay off all the notes in one fell swoop? THEY ONLY OWE $673,092 and THEY HAVE A MARKET CAP OF ~ 24 MILLION as of this morning (Aug 28th) That's peanuts in debt compared to what this company is trading at RIGHT NOW. NOTHING SCARY ABOUT IT. PERIOD.
CELZ Outstanding Shares in December 2017: 106M Stock was 1.3 pennies
CELZ Outstanding Shares in March 2018: 188M Stock was .0025 pennies
CELZ Outstanding Shares TODAY 2018: 717M Stock today is 3.6 pennies!!! THIS IS 1,703% INCREASE IN PPS SINCE DEC and they have had all this SCARY TOXIC DEBT CONVERT WITH MORE TO COME. Sweet. Keep it coming!
IS IT POSSIBLE FOR OUTSTANDING SHARES TO GO UP AND THE STOCK PRICE WILL TOO? YEEESSSSSSSSSSSSS. DON'T BE FOOLED BY ONE SIDED ARGUMENT.
Big Pharma who owns the BLUE PILL for ED has 5.8 BILLION Outstanding Shares and trades this morning at $41.53. Don't take my word for it: BigBluePillStatsClickHere
FIVE BILLION EIGHT HUNDRED MILLION SHARES OUT. Where are their OS haters? And they are trading in the $40's people ($52B in Revs). CELZ WILL NOT be as big in revenue or OS any time soon BUT, if they do measly $1B in revenue from their GLOBAL CaverStem sales coming soon to a doctor near you!, and they have OS maxed at ~850M with all the SCARY TOXIC notes fully converting, then CELZy could easily trade at $1.17 VERY SOON. Even if this blips up to 1 BILLION OS, it's still a buck a share stock. AND THAT IS ONLY PONDERING ED TREATMENT. What about SPINESTEM? And the other MAJOR PATENTS that have 7 - 20 YEARS of LIFE LEFT? Sheesh. Some just have real SKILLS and they build REAL companies like CELZ. Others just try to scare people for a living and make a pittance. So sad but not my problem! Go CELZ!!!!!
Here be the FACTS since they seem so hard to find:
THE FOLLOWING COMES DIRECTLY FROM THE SEC.GOV ARCHIVES FOR CELZ's June 30, 2018 10Q Reported PERFECTLY ON TIME on August 14, 2018:
NOTE 4 – DEBT
$400,000 Convertible Debenture
On May 2, 2017, the Company entered into a convertible debenture agreement with a third party for an aggregate principal amount of up to $400,000, for which up to $360,000 in proceeds is to be received. On May 2, 2017, the Company received the first tranche of proceeds of $85,000 for which the Company issued a convertible debenture in the face amount of $100,000. During the three and six month period ended June 30, 2018 the Company amortized $54,085 to interest expense. As of June 30, 2018, a discount of $0 remained. During the three and six month periods ended June 30, 2018, the lender converted $54,200 of principal into 23,485,183 shares of common stock. On March 23, 2018 the Company paid the lender $1,000 to extinguish the remaining principal balance. As of June 30, 2018 the Company had fulfilled all the obligations of the debenture.
$115,000 Convertible Note
On April 10, 2017, the Company entered into a convertible note agreement with a third party for an aggregate principal amount of $115,000, for which $103,250 in proceeds were received on May 5, 2017. Under the terms of the agreement, the convertible note incurs interest at 10% per annum and has a maturity date of January 10, 2018. The note holder has notified the company they do not consider the note in default and their intent is to continue converting the remaining principal and accrued interest into common shares. During the three and six month periods ended June 30, 2018, the Company amortized $0 and $4,600 to interest expense respectively. As of June 30, 2018, a discount of $0 remained.
The conversion price is subject to adjustment in the case of stock splits, stock dividends, combinations of shares and similar recapitalization transactions and any issuances of securities below the conversion price of the convertible note. On the date of issuance, the Company accounted for the conversion feature and the warrants as derivative liabilities, see Note 5. Derivative accounting applies as the conversion price is variable and does not have a floor as to the number of common shares in which could be converted. Thus, if the convertible note is not repaid prior to the note being converted significant pressure maybe put on the Company’s stock price and additional dilution of current shareholders may take place. During the three and six month periods ended June 30, 2018, the lender converted $70,341 of principal, interest and fees into 80,306,141 common shares $134,127 of principal, interest and fees into 145,929,641 common shares respectively. As of June 30, 2018 the Company had fulfilled all the obligations of the note.
$55,000 Convertible Note
On April 24, 2017, the Company entered into a convertible note agreement with a third party for an aggregate principal amount of $55,000, for which $47,500 in proceeds were received on May 8, 2017. Under the terms of the agreement, the convertible note incurs interest at 10% per annum and has a maturity date of April 24, 2018. During the three and six month periods ended June 30, 2018 the Company amortized $0 and $17,863 to interest expense respectively. As of June 30, 2018, a discount of $0 remained.
The conversion price is subject to adjustment in the case of stock splits, stock dividends, combinations of shares and similar recapitalization transactions and any issuances of securities below the conversion price of the convertible note. On the date of issuance, the Company accounted for the conversion feature and the warrants as derivative liabilities, see Note 5. Derivative accounting applies as the conversion price is variable and does not have a floor as to the number of common shares in which could be converted. Thus, if the convertible note is not repaid prior to the note being converted significant pressure maybe put on the Company’s stock price and additional dilution of current shareholders may take place. The warrants were considered derivative liabilities as there are various reset provisions to the exercise price based upon additional issuances of common stock and equivalents. As of June 30, 2018 the Company had fulfilled all the obligations of the note.
$50,000 Secured Convertible Note
On June 26, 2017, the Company entered into a convertible note agreement with a third party for an aggregate principal amount of $50,000, for which $50,000 in proceeds were received on June 26, 2017. Under the terms of the agreement, the convertible note incurs interest at 12% per annum and matured on December 26, 2017. The convertible note has since been retired through a debt exchange agreement with a third party dated March 8, 2018, see "$60,000 Convertible Note - Global" below.
$50,000 Convertible Note
On July 19, 2017, the Company entered into a convertible note agreement with a third party for an aggregate principal amount of $50,000, for which $43,000 in proceeds were received on July 25, 2017. Under the terms of the agreement, the convertible note incurs interest at 5% per annum and has a maturity date of July 19, 2018. During the three and six months ended June 30, 2018 the Company amortized $15,068 and $27,397 respectively to interest expense. As of June 30, 2018, a discount of $0 remained.
During the three and six month periods ended June 30, 2018, the lender converted $31,720 of principal, interest and fees into 35,756,381 common shares $54,697 of principal, interest and fees into 56,453,381 common shares respectively. As of June 30, 2018 there were 333,470,447 common shares reserved with our transfer agent. As of June 30, 2018 the Company had fulfilled all the obligations of the note.
-------------------------------------------2018 BEGINS
$30,000 Convertible Note
On January 9, 2018, the Company entered into a convertible note agreement with a third party for an aggregate principal amount of $30,000, for which 12,500,000 outstanding warrants from the convertible note dated April 24, 2017 were extinguished. The difference between the convertible note, the conversion feature and the value of the warrants was recorded as a derivative loss. No proceeds were received in conjunction with this note. Under the terms of the agreement, the convertible note incurs interest at 8% per annum and has a maturity date of January 9, 2019. The convertible note is convertible upon issuance and convertible into shares of the Company’s stock at a conversion price equal to 60% of the lowest traded price of the Company’s common stock during the previous 20 trading days preceding the conversion date. The Company is required at all times to reserve shares of the Company’s common stock equal to three times the number of common shares the convertible note is convertible into.
The conversion price is subject to adjustment in the case of stock splits, stock dividends, combinations of shares and similar recapitalization transactions and any issuances of securities below the conversion price of the convertible note. On the date of issuance, the Company accounted for the conversion feature as a derivative liability, see Note 5. Derivative accounting applies as the conversion price is variable and does not have a floor as to the number of common shares in which could be converted. Thus, if the convertible note is not repaid prior to the note being converted significant pressure maybe put on the Company’s stock price and additional dilution of current shareholders may take place. As of June 30, 2018, there were 0 shares reserved with our transfer agent with a potential of up to 1,629,600 being reserved if and when the lender issues a request to our transfer agent.
In the event of default, the holder has the right to require the Company to pay an amount equal to 120% multiplied by the then outstanding entire balance of the note, including principal and accrued unpaid interest. In addition, the default interest rate would increase to 24%.
The Company has the option to redeem the convertible notes at any time within 180 days from the date of issuance at 120% of the principal and interest; and after 180 days the right of prepayment expires.
During the three and six month periods ended June 30, 2018, the lender converted $ 27,744 of principal, interest and fees into 4,533,351 common shares.
$44,000 Convertible Note
On January 17, 2018, the Company entered into a convertible note agreement with a third party for an aggregate principal amount of $44,000, for which $19,000 in proceeds were received on January 23, 2018 and $19,000 in proceeds were received on February 26, 2018. Under the terms of the agreement, the convertible note incurs interest at 10% per annum and has a maturity date of January 17, 2019. The convertible note is convertible upon issuance and convertible into shares of the Company’s stock at a conversion price equal to 60% of the lowest traded price of the Company’s common stock during the previous 20 trading days preceding the conversion date. The Company is required at all times to reserve shares of the Company’s common stock equal to three times the number of common shares the convertible note is convertible into. The Company is amortizing the on issuance discount of $4,000, legal fees of $2,000 and the remaining discount of $34,324 due to the recording of a derivative liability as discussed in Note 5. The Company is amortizing the total discount of $40,324 to interest expense using the straight-line method over the term of the loan. During the three and six month periods ended June 30, 2018 the Company amortized $32,259 and $40,324 to interest expense respectively. As of June 30, 2018, a discount of $0 remained.
The conversion price is subject to adjustment in the case of stock splits, stock dividends, combinations of shares and similar recapitalization transactions and any issuances of securities below the conversion price of the convertible note. On the date of issuance, the Company accounted for the conversion feature as a derivative liability, see Note 5. Derivative accounting applies as the conversion price is variable and does not have a floor as to the number of common shares in which could be converted. Thus, if the convertible note is not repaid prior to the note being converted significant pressure maybe put on the Company’s stock price and additional dilution of current shareholders may take place. As of June 30, 2018, there were 125,259,293 shares reserved with our transfer agent with a potential of 0 being reserved if and when the lender issues a request to our transfer agent.
In the event of default, the holder has the right to require the Company to pay an amount equal to 120% multiplied by the then outstanding entire balance of the note, including principal and accrued unpaid interest. In addition, the default interest rate would increase to 24%.
There is no option for the Company to redeem the convertible note prior to maturity.
During the three and six month periods ended June 30, 2018, the lender converted $44,000 of principal, interest and fees into 27,518,485 common shares. As of June 30, 2018 the Company had fulfilled all the obligations of the note.
$12,500 Convertible Note
On January 22, 2018, the Company entered into a convertible note agreement with a third party for an aggregate principal amount of $12,500, in exchange for the release of reserved shares to the Company. Under the terms of the agreement, the convertible note incurs interest at 8% per annum and has a maturity date of January 22, 2019. The convertible note is convertible upon issuance and convertible into shares of the Company’s stock at a conversion price equal to 60% of the lowest traded price of the Company’s common stock during the previous 20 trading days preceding the conversion date.
The conversion price is subject to adjustment in the case of stock splits, stock dividends, combinations of shares and similar recapitalization transactions and any issuances of securities below the conversion price of the convertible note. On the date of issuance, the Company accounted for the conversion feature as a derivative liability, see Note 5. Derivative accounting applies as the conversion price is variable and does not have a floor as to the number of common shares in which could be converted. Thus, if the convertible note is not repaid prior to the note being converted significant pressure maybe put on the Company’s stock price and additional dilution of current shareholders may take place.
In the event of default, the holder has the right to require the Company to pay an amount equal to 120% multiplied by the then outstanding entire balance of the note, including principal and accrued unpaid interest. In addition, the default interest rate would increase to 24%.
The Company has the option to redeem the convertible note within 180 days from the date of issuance at 120% of the principal and interest. After 180 days the right of prepayment expires.
During the three and six month periods ended June 30, 2018, the lender converted $12,925 of principal, interest and fees into 2,111,873 common shares. As of June 30, 2018 the Company had fulfilled all the obligations of the note.
$53,000 Convertible Note
On February 15, 2018, the Company entered into a convertible note agreement with a third party for an aggregate principal amount of $53,000, for which $50,000 in proceeds were received on February 22, 2018 . Under the terms of the agreement, the convertible note incurs interest at 12% per annum and has a maturity date of February 15, 2019. The convertible note is convertible upon issuance and convertible into shares of the Company’s stock at a conversion price equal to 61% of the average of the two lowest traded prices of the Company’s common stock during the previous 15 trading days preceding the conversion date. The Company is required at all times to reserve shares of the Company’s common stock equal to three times the number of common shares the convertible note is convertible into. The Company is amortizing the on issuance discount of $3,000 and the remaining discount of $50,000 due to the recording of a derivative liability as discussed in Note 5. The Company is amortizing the total discount of $53,000 to interest expense using the straight-line method over the term of the loan. During the three and six months ended June 30, 2018 the Company amortized $46,611 and $53,000 to interest expense respectively. As of June 30, 2018, a discount of $0 remained.
The conversion price is subject to adjustment in the case of stock splits, stock dividends, combinations of shares and similar recapitalization transactions and any issuances of securities below the conversion price of the convertible note. On the date of issuance, the Company accounted for the conversion feature as a derivative liability, see Note 5. Derivative accounting applies as the conversion price is variable and does not have a floor as to the number of common shares in which could be converted. Thus, if the convertible note is not repaid prior to the note being converted significant pressure maybe put on the Company’s stock price and additional dilution of current shareholders may take place. As of June 30, 2018, there were 0 shares reserved with our transfer agent with a potential of up to 256,031,833 being reserved if and when the lender issues a request to our transfer agent.
In the event of default, the holder has the right to require the Company to pay an amount equal to 120% multiplied by the then outstanding entire balance of the note, including principal and accrued unpaid interest. In addition, the default interest rate would increase to 22%.
The Company has the option to redeem the convertible notes within 90 days from the date of issuance at 115% of the principal and interest; between 91 and to 180 days from the date of issuance at 120% of the principal and interest; and after 180 days the right of prepayment expires.
On April 26, 2018 the Company retired the note with a payment of $82,084 to the note holder. A derivative liability gain of $279,795 was recorded to reflect the retirement of the derivative liability.
$27,500 Convertible Note
On March 9, 2018, the Company entered into a convertible note agreement with a third party for an aggregate principal amount of $27,500, for which proceeds of $23,500 were received on March 9, 2018. Under the terms of the agreement, the convertible note incurs interest at 10% per annum and has a maturity date of March 9, 2019. The convertible note is convertible upon issuance and convertible into shares of the Company’s stock at a conversion price equal to 60% of the lowest traded price of the Company’s common stock during the previous 20 trading days preceding the conversion date. The Company is amortizing the discount of $27,500 due to on issuance discount of $4,000 and the recording of a derivative liability as discussed in Note 5. The Company is amortizing the discount of $27,500 to interest expense using the straight-line method over the term of the loan. During the three and six months ended June 30, 2018 the Company amortized $25,842 and $27,500 to interest expense respectively. As of June 30, 2018, a discount of $0 remained.
The conversion price is subject to adjustment in the case of stock splits, stock dividends, combinations of shares and similar recapitalization transactions and any issuances of securities below the conversion price of the convertible note. On the date of issuance, the Company accounted for the conversion feature as a derivative liability, see Note 5. Derivative accounting applies as the conversion price is variable and does not have a floor as to the number of common shares in which could be converted. Thus, if the convertible note is not repaid prior to the note being converted significant pressure maybe put on the Company’s stock price and additional dilution of current shareholders may take place.
In the event of default, the holder has the right to require the Company to pay an amount equal to 150% multiplied by the then outstanding entire balance of the note, including principal and accrued unpaid interest. In addition, the default interest rate would increase to 24%.
The Company has the option to redeem the convertible notes within 30 days from the date of issuance at 115% of the principal and interest; between 31 and to 60 days from the date of issuance at 120% of the principal and interest; between 61 and to 90 days from the date of issuance at 125% of the principal and interest; between 91 and to 120 days from the date of issuance at 130% of the principal and interest; between 121 and to 150 days from the date of issuance at 135% of the principal and interest; between 151 and 180 days from issuance at 140% of principal and interest; and after 180 days the right of prepayment expires.
During the three and six month periods ended June 30, 2018, the lender converted $28,344 of principal, interest and fees into 4,631,346 common shares. As of June 30, 2018 the Company had fulfilled all the obligations of the note.
$60,000 Convertible Note
March 9, 2018, the Company entered into a convertible note agreement with a third party for an aggregate principal amount of $60,000, in exchange for the extinguishment of the outstanding principal due on the convertible note dated June 26, 2017, see disclosure above for "$50,000 Secured Convertible Note - WBRE". No proceeds were received in conjunction with the exchange of this convertible note. Under the terms of the agreement, the convertible note incurs interest at 10% per annum and has a maturity date of March 9, 2019. The convertible note is convertible upon issuance and convertible into shares of the Company’s stock at a conversion price equal to 60% of the lowest traded price of the Company’s common stock during the previous 20 trading days preceding the conversion date. At no additional cost, we issued to the note holder 30,000,000 five-year warrants to purchase common stock at $0.01, subject to adjustment if we issue securities at less than the exercise price. The warrants are exercisable on a cashless basis.
The conversion price is subject to adjustment in the case of stock splits, stock dividends, combinations of shares and similar recapitalization transactions and any issuances of securities below the conversion price of the convertible note. On the date of issuance, the Company accounted for the conversion feature as a derivative liability, see Note 5. Derivative accounting applies as the conversion price is variable and does not have a floor as to the number of common shares in which could be converted. Thus, if the convertible note is not repaid prior to the note being converted significant pressure maybe put on the Company’s stock price and additional dilution of current shareholders may take place.
In the event of default, the holder has the right to require the Company to pay an amount equal to 150% multiplied by the then outstanding entire balance of the note, including principal and accrued unpaid interest. In addition, the default interest rate would increase to 24%.
The Company has the option to redeem the convertible notes within 180 days from the date of issuance at 120% of the principal and interest; and after 180 days the right of prepayment expires.
At the date of the agreement, the Company determined that the transactions qualified for extinguishment accounting whereby the transaction was accounted for at fair market value with the excess value between the fair value of the old note and new note was accounted for as an extinguishment loss of $154,284.
During the three and six month periods ended June 30, 2018, the lender converted $60,147 of principal, interest and fees into 45,665,203 common shares. As of June 30, 2018 the Company had fulfilled all the obligations of the note.
$115,000 Convertible Note
On March 13, 2018, the Company entered into a convertible note agreement with a third party for an aggregate principal amount of $115,000, for which $97,250 in proceeds were received on March 19, 2018 . Under the terms of the agreement, the convertible note incurs interest at 10% per annum and has a maturity date of December 13, 2018. The convertible note is convertible upon issuance and convertible into shares of the Company’s stock at a conversion price equal to 60% of the average of the two lowest traded prices of the Company’s common stock during the previous 25 trading days preceding the conversion date. The Company is required at all times to reserve shares of the Company’s common stock equal to six times the number of common shares the convertible note is convertible into. The Company is amortizing the original issuance discount of $15,000 legal fees of $2,750 and the remaining discount of $97,250 due to the recording of a derivative liability as discussed in Note 5. The Company is amortizing the total discount of $115,000 to interest expense using the straight-line method over the term of the loan. During the three and six months ended June 30, 2018 the Company amortized $38,055 and $45,582 to interest expense respectively. As of June 30, 2018, a discount of $69,418 remained.
The conversion price is subject to adjustment in the case of stock splits, stock dividends, combinations of shares and similar recapitalization transactions and any issuances of securities below the conversion price of the convertible note. On the date of issuance, the Company accounted for the conversion feature as a derivative liability, see Note 5. Derivative accounting applies as the conversion price is variable and does not have a floor as to the number of common shares in which could be converted. Thus, if the convertible note is not repaid prior to the note being converted significant pressure maybe put on the Company’s stock price and additional dilution of current shareholders may take place. As of June 30, 2018, there were 500,000,000 shares reserved with our transfer agent with a potential of 114,429,224 being reserved if and when the lender issues a request to our transfer agent.
In the event of default, the holder has the right to require the Company to pay an amount equal to 125% multiplied by the then outstanding entire balance of the note, including principal and accrued unpaid interest. In addition, the default interest rate would increase to 24%.
The Company has the option to redeem the convertible notes within 90 days from the date of issuance at 125% of the principal and interest; between 91 and to 180 days from the date of issuance at 140% of the principal and interest; and after 180 days the right of prepayment expires.
$48,000 Convertible Note
On March 15, 2018, the Company entered into a convertible note agreement with a third party for an aggregate principal amount of $48,000, for which $45,600 in proceeds were received on March 20, 2018 . Under the terms of the agreement, the convertible note incurs interest at 10% per annum and has a maturity date of March 15, 2019. The convertible note is convertible upon issuance and convertible into shares of the Company’s stock at a conversion price equal to 63% of the average of the two lowest traded prices of the Company’s common stock during the previous 12 trading days preceding the conversion date. The Company is required at all times to reserve shares of the Company’s common stock equal to six times the number of common shares the convertible note is convertible into. The Company is amortizing legal fees of $2,400 and the remaining discount of $45,600 due to the recording of a derivative liability as discussed in Note 5. The Company is amortizing the total discount of $48,000 to interest expense using the straight-line method over the term of the loan. During the three and months ended June 30, 2018 the Company amortized $45,896 and $48,000 to interest expense respectively. As of June 30, 2018, a discount of $0 remained.
The conversion price is subject to adjustment in the case of stock splits, stock dividends, combinations of shares and similar recapitalization transactions and any issuances of securities below the conversion price of the convertible note. On the date of issuance, the Company accounted for the conversion feature as a derivative liability, see Note 5. Derivative accounting applies as the conversion price is variable and does not have a floor as to the number of common shares in which could be converted. Thus, if the convertible note is not repaid prior to the note being converted significant pressure maybe put on the Company’s stock price and additional dilution of current shareholders may take place. As of June 30, 2018, there were 0 shares reserved with our transfer agent with a potential of 0 being reserved if and when the lender issues a request to our transfer agent.
In the event of default, the holder has the right to require the Company to pay an amount equal to 120% multiplied by the then outstanding entire balance of the note, including principal and accrued unpaid interest. In addition, the default interest rate would increase to 24%.
The Company has the option to redeem the convertible notes within 60 days from the date of issuance at 110% of the principal and interest; between 61 and to 120 days from the date of issuance at 124% of the principal and interest; between 121 days and to 180 days from the date of issuance at 138%; and after 180 days the right of prepayment expires.
On April 25, 2018 the Company retired the note with a payment of $60,000 to the note holder. A derivative liability gain of $209,076 was recorded to reflect the retirement of the derivative liability.
$110,000 Convertible Note
On April 3, 2018, the Company entered into a convertible note agreement with a third party for an aggregate principal amount of $110,000, for which $95,000 in proceeds were received on April 3, 2018 . Under the terms of the agreement, the convertible note incurs interest at 10% per annum and has a maturity date of March 29, 2019. The convertible note is convertible upon issuance and convertible into shares of the Company’s stock at a conversion price equal to 60% of the lowest traded price of the Company’s common stock during the previous 20 trading days preceding the conversion date. The Company is required at all times to reserve shares of the Company’s common stock equal to five times the number of common shares the convertible note is convertible into. The Company is amortizing legal fees of $2,652 and the remaining discount of $107,348 due to the recording of a derivative liability as discussed in Note 5. The Company is amortizing the total discount of $110,000 to interest expense using the straight-line method over the term of the loan. During the three and months ended June 30, 2018 the Company amortized $26,521 to interest expense. As of June 30, 2018, a discount of $83,479 remained. At no additional cost, we issued to the note holder 11,000,000 five-year warrants to purchase common stock at $0.01, subject to adjustment if we issue securities at less than the exercise price. The warrants are exercisable on a cashless basis.
The conversion price is subject to adjustment in the case of stock splits, stock dividends, combinations of shares and similar recapitalization transactions and any issuances of securities below the conversion price of the convertible note. On the date of issuance, the Company accounted for the conversion feature as a derivative liability, see Note 5. Derivative accounting applies as the conversion price is variable and does not have a floor as to the number of common shares in which could be converted. Thus, if the convertible note is not repaid prior to the note being converted significant pressure maybe put on the Company’s stock price and additional dilution of current shareholders may take place. As of June 30, 2018, there were 118,000,000 shares reserved with our transfer agent with a potential of 92,000,000 being reserved if and when the lender issues a request to our transfer agent.
In the event of default, the holder has the right to require the Company to pay an amount equal to 150% multiplied by the then outstanding entire balance of the note, including principal and accrued unpaid interest. In addition, the default interest rate would increase to 18%.
The Company has the option to redeem the convertible notes within 180 days from the date of issuance at 140% of the principal and interest. After 180 days the right of prepayment expires.
$110,000 Convertible Note
On April 11, 2018, the Company entered into a convertible note agreement with a third party for an aggregate principal amount of $110,000, for which $100,000 in proceeds were received. Under the terms of the agreement, the convertible note incurs interest at 10% per annum and has a maturity 12 months from the effective date of payment. The convertible note is convertible upon issuance and convertible into shares of the Company’s stock at a conversion price equal to 60% of the lowest trading price of the Company’s common stock during the previous 20 trading days preceding the conversion date. The Company is required at all times to reserve shares of the Company’s common stock equal to three times the number of common shares the convertible note is convertible into. The Company is amortizing an on-issuance discount of $10,000 and the remaining discount of $100,000 due to the recording of a derivative liability as discussed in Note 5. The Company is amortizing the total discount of $110,000 to interest expense using the straight-line method over the term of the loan. During the three and months ended June 30, 2018 the Company amortized $24,110 to interest expense. As of June 30, 2018, a discount of $85,890 remained. At no additional cost, we issued to the note holder 11,000,000 five-year warrants to purchase common stock at $0.01, subject to adjustment if we issue securities at less than the exercise price. The warrants are exercisable on a cashless basis.
The conversion price is subject to adjustment in the case of stock splits, stock dividends, combinations of shares and similar recapitalization transactions and any issuances of securities below the conversion price of the convertible note. On the date of issuance, the Company anticipates that it will account for conversion feature as a derivative liability. Derivative accounting applies as the conversion price is variable and does not have a floor as to the number of common shares in which could be converted. Thus, if the convertible note is not repaid prior to the note being converted significant pressure maybe put on the Company’s stock price and additional dilution of current shareholders may take place. As of June 30, 2018, there were 18,333,333 shares reserved with our transfer agent with a potential of 55,103,411 being reserved if and when the lender issues a request to our transfer agent.
In the event of default, the holder has the right to require the Company to pay an amount equal to 150% multiplied by the then outstanding entire balance of the note, including principal and accrued unpaid interest. In addition, the default interest rate would increase to 18%.
The Company has the option to redeem the convertible notes within 180 days from the date of issuance at 140% of the principal and interest. After 180 days the right of prepayment expires.
$110,000 Convertible Note
On April 13, 2018, the Company entered into a convertible note agreement with a third party for an aggregate principal amount of $110,000, for which $99,000 in proceeds were received. Under the terms of the agreement, the convertible note incurs interest at 10% per annum and has a maturity date of March 29, 2019. The convertible note is convertible upon issuance and convertible into shares of the Company’s stock at a conversion price equal to 60% of the lowest trading price of the Company’s common stock during the previous 20 trading days preceding the conversion date. The Company is required at all times to reserve shares of the Company’s common stock equal to three times the number of common shares the convertible note is convertible into. The Company is amortizing an on-issuance discount of $10,000, legal fees of $1,000 and the remaining discount of $99,000 due to the recording of a derivative liability as discussed in Note 5. The Company is amortizing the total discount of $110,000 to interest expense using the straight-line method over the term of the loan. During the three and months ended June 30, 2018 the Company amortized $24,110 to interest expense. As of June 30, 2018, a discount of $85,890 remained.
The conversion price is subject to adjustment in the case of stock splits, stock dividends, combinations of shares and similar recapitalization transactions and any issuances of securities below the conversion price of the convertible note. On the date of issuance, the Company anticipates that it will account for conversion feature as a derivative liability. Derivative accounting applies as the conversion price is variable and does not have a floor as to the number of common shares in which could be converted. Thus, if the convertible note is not repaid prior to the note being converted significant pressure maybe put on the Company’s stock price and additional dilution of current shareholders may take place. As of June 30, 2018, there were 13,000,000 shares reserved with our transfer agent with a potential of 55,103,411 being reserved if and when the lender issues a request to our transfer agent.
In the event of default, the holder has the right to require the Company to pay an amount equal to 150% multiplied by the then outstanding entire balance of the note, including principal and accrued unpaid interest. In addition, the default interest rate would increase to 22%.
The Company has the option to redeem the convertible notes within 30 days from the date of issuance at 115% of the principal and interest; between 31 and to 60 days from the date of issuance at 120% of the principal and interest; between 61 and to 90 days from the date of issuance at 125% of the principal and interest; between 91 and to 120 days from the date of issuance at 130% of the principal and interest; between 121 and to 150 days from the date of issuance at 135% of the principal and interest; between 151 and to 180 days from the date of issuance at 140% of the principal and interest; and after 180 days the right of prepayment expires.
$108,000 Convertible Note
On May 14, 2018, the Company entered into a convertible note agreement with a third party for an aggregate principal amount of $108,000, for which $94,960 in proceeds were received. Under the terms of the agreement, the convertible note incurs interest at 8% per annum and has a maturity date of May 14, 2019. The convertible note is convertible upon issuance and convertible into shares of the Company’s stock at a conversion price equal to 60% of the lowest trading price of the Company’s common stock during the previous 20 trading days preceding the conversion date. The Company is required at all times to reserve shares of the Company’s common stock equal to three times the number of common shares the convertible note is convertible into. The Company is amortizing an on-issuance discount of $8,000, legal fees of $5,040 and the remaining discount of $94,960 due to the recording of a derivative liability as discussed in Note 5. The Company is amortizing the total discount of $108,000 to interest expense using the straight-line method over the term of the loan. During the three and six months ended June 30, 2018 the Company amortized $13,907 to interest expense. As of June 30, 2018, a discount of $94,093 remained.
The conversion price is subject to adjustment in the case of stock splits, stock dividends, combinations of shares and similar recapitalization transactions and any issuances of securities below the conversion price of the convertible note. On the date of issuance, the Company anticipates that it will account for conversion feature as a derivative liability. Derivative accounting applies as the conversion price is variable and does not have a floor as to the number of common shares in which could be converted. Thus, if the convertible note is not repaid prior to the note being converted significant pressure maybe put on the Company’s stock price and additional dilution of current shareholders may take place. As of June 30, 2018, there were 35,000,000 shares reserved with our transfer agent with a potential of 53,486,543 being reserved if and when the lender issues a request to our transfer agent.
In the event of default, the holder has the right to require the Company to pay an amount equal to 150% multiplied by the then outstanding entire balance of the note, including principal and accrued unpaid interest. In addition, the default interest rate would increase to 24%.
There is no option to pre-pay this note.
$108,000 Note
On June 27, 2018, the Company entered into a note agreement with a third party for an aggregate principal amount of $108,000, for which $100,000 in proceeds were received. Under the terms of the agreement, the note incurs interest at 8% per annum and has a maturity date of June 27, 2019. The Company is amortizing the on-issuance discount of $8,000 to interest expense using the straight-line method over the term of the loan. During the three and six months ended June 30, 2018 the Company amortized $66 to interest expense. As of June 30, 2018, a discount of $7,934 remained.
In the event of default, the holder has the right to require the Company to pay an amount equal to 120% multiplied by the then outstanding entire balance of the note, including principal and accrued unpaid interest. In addition, the default interest rate would increase to 24%.
As of June 30, 2018, future loan maturities are as follows:
For the year ended December 31,
2018 118,434
2019 554,658
Total $ 673,092
Hello CELZ Investors and soon to be joining!
Key Stats:
DECEMBER 2017: Outstanding Shares were 106M shares and PPS was $0.0135 - They had a single doctor (Dr. Gershman) who did the 1st commercial CaverStem procedure sometime in either Dec or January ('18).
JUNE 2018: Outstanding Shares were 623M shares and PPS was AVG $0.035 (Stock was UP 1,592% even with the massive INCREASE OF OS i.e. dilution) - They still had 1 official CaverStem doctor (still Gershman) BUT, they had done the American Urological Association conference in May and they had PR'd that there were MANY doctors interested. Interest = PPS POTENTIAL. They also showed a $20,000 prepayment in June from a new CaverStem customer (i.e. new licensed doctor) Page 35 of 39 in Cash Flow notes from June 30th 10Q from SEC.gov.
DECEMBER 2018???: EVEN IF OS GROWS TO 1 BILLION...PPS COULD BE 50 CENTS BASED ON THIS PROGRESSION!!!!SUPER SCARY IF YOU MISS IT!!! - AS of right now (AUGUST 27, 2018) we have 8 named CaverStem MD's that were welcomed in the PR on August 14th. There are doctors in Switzerland and Russia already in play AND if that weren't positive enough, an impressive Urologist in ROME ITALY reached out to CELZ MGMT on Facebook's CaverStem page this weekend asking about licensing! (Cool Italian Doctor asking to become a CaverStem Provider!) So, in six months ended June 30th, the stock went up 1,592% while OS when up 517M shares. SOAK THIS UP. They only had one "official" CaverStem doctor listed (Gershman). Now, since June 30th, they have announced 8+ doctors who must be paying a $20k licensing fee per plus buying the equipment and the kits. In other words, REVENUE.
So ask yourself, if they have started cleaning up the debt picture (they paid off another $268K of the loans BEFORE they converted), they only have 4 convertible notes left (based on our understanding) before they are CLEAR OF THE "Toxic" DILUTION EFFECTS, what does the PPS do if they keep up this pace? ADDING REVENUES DAILY. REDUCING DEBT and/or getting conversions done. EVEN IF THEY ADD ANOTHER 98M to OS, that can be swallowed up by REVENUE. THIS THING HAS POTENTIAL and IT IS GETTING GLOBAL ATTENTION.
Another American Urological Association Convention in Chicago next week - AKA CAVERSTEM DOCTOR SEARCH AND SECURE MISSION. CaverStem will be exhibiting there. You don't go to trade-shows if you are shutting down an operation due to lack of funds. You just don't. Trade shows are miserable work and expensive. You go if you have money and you expect the misery to be worth it.
Results from a 100 patient 12 month long study by top-shelf academic and medical researches will be PEER REVIEWED in conjunction with Los Angeles Biomedical Institute. The study will be concluded and likely shared within the next 30-40 days +/- Notable quote from their LI page: It is often said, “someday they will find a way.” When it comes to discovery science that drives medical breakthroughs, “they” are here at LA BioMed.) CELZY is @ LA BioMed. That's cool stuff.
If you've made it this far...a reasonable question for to ponder:
Why would any of these highly reputable and distinguished 8 doctors (in US only) sign up to become CaverStem licensees BEFORE the clinical trial was complete and peer reviewed? Don't you think they either got to see the results early, i.e. under confidentiality agreements, or they have some other reason that is worth NOT WAITING another simple month to see the proof in all of its peer reviewed glory? I mean, seriously, these gentlemen have not only passed medical bar exams, been practicing for 20-40 years, and are trusted with the parts of the human body most sacred, but they have real credentials and distinguished honors. Surely they wouldn't sign up to do some "crazy" ineffective medical procedure without being damn well certain of the benefits/efficacy across the average population. Really. I just can't fathom this many docs being duped into this. One? Maybe. Two, possibly but unlikely. EIGHT and more coming? No way.
Feel better about the near future folks!
Some hard facts about the way CELZ MGMT has been working on the debt...
Here is the breakdown on the loans/notes they got this 2018 year (they Already Paid ALL of 2017's notes off):
#1. January 9, 2018 - $30,000 convertible note (PAID-IN-FULL ALREADY)
#2. January 17, 2018 - $44,000 convertible note (PAID-IN-FULL ALREADY)
#3. January 22, 2018 - $12,500 convertible note (PAID-IN-FULL ALREADY)
#4. February 15, 2018 - $53,000 convertible note (PAID-IN-FULL ALREADY)
#5. March 9, 2018 - $27,500 convertible note (PAID-IN-FULL ALREADY)
#6. March 9, 2018 - $60,000 convertible note (PAID-IN-FULL ALREADY)
#7. March 13, 2018 - $115,000 convertible note (As of June 30: $69.4k left - Already Paid 40% OFF)
#8. March 15, 2018 - $48,000 convertible note (PAID-IN-FULL ALREADY)
#9. April 3, 2018 - $110,000 convertible note (As of June 30: $83.4k left - Already Paid 25% OFF)
#10. April 11, 2018 - $110,000 convertible note (As of June 30: $85.8k left - Already Paid 25% OFF)
#11. April 13, 2018 - $110,000 convertible note ( As of June 30: $85.9k left - Already Paid 25% OFF)
#12. May 14, 2018 - $108,000 convertible note (As of June 30: $94.1k left - Already Paid 13% OFF)
BIG PIVOT FOR GETTING HEALTHY "REGULAR" BUSINESS LOANS HAPPENS ON JUNE 27th and CONTINUES NOW!!!!
#13. June 27, 2018 - $108,000 REGULAR BUSINESS LOAN NON-CONVERTIBLE!!!!!! 1 Year TERM @ a reasonable 8% Interest! (AS OF JUNE 30, 2018: $7,934 left!!!!!) They paid down over $100k in three days! 93% PAID OFF ALREADY!
#14. On August 8, 2018 the company sought a SHORT TERM, NON-CONVERTIBLE LOAN in the amount of $107,000 due in Cash on AUGUST 22nd.
Hello August 14th! -- My one allowed post for the day.
Couple great quotes for all of us to keep in mind for today and:
"Many of life's failures are people who did not realize how close they were to success when they gave up." - Thomas Edison
"Elegance is for tailors...don't believe in something because it's a beautiful formula." - Albert Einstein
My comments regarding those are these:
1. No matter what happens with the PPS today or this week doesn't undermine the solid business proposition for owning CELZ as the months turn to winter. This is hardly the time to give up with all the framework being put in place -- all of this is especially true if you're a bag holder (such as me at this time...I've loaded extensively in the 3,4 and 5's with some in the 6's.)
2. I have been extremely consistent since my day one posting on this board that charts do not matter as respects CELZ. This is not to say one cannot make money flipping CELZ using charts. The old adage that "the measure of man is in his ability to hold two opposing thoughts in his hand and not go crazy" comes into play here. I have an academic background in advanced investments so I can appreciate all the technical efforts and seemingly predictive outcomes. But more valuable than that, I have real world experience in business and start-ups that have resolutely confirmed for me that charts and financial modeling is really just a fools errand in the big picture as they are either "self-fulfilling" by way of herd mentality (short-term effect) or they are completely summary aka rearward looking. Ultimately, a thing is either going to work or it is not. It's as simple as that. CELZ is either going to start making money (and maybe a lot!) or it's going to fold. It is way too early to say which but the evidence of their build-out of their patent portfolio suggests it IS going to make it, big time and in due time.
For all legitimate long holders who face the daily MM games and all-knowing chartists with their super solid gonna happen BS just remember that CELZ is an INVESTMENT predicated on solid fundamentals that they happen to be delivering in spades. I want PPS to go up daily like many, and I too watch it perilously like a hawk, but my experience in both finance and scientific start-ups keeps me grounded to the reality that it's likely going to get down right ugly and bloody before it gets glorious. At this stage in the game, it isn't about what's fair and just, it's about survival. When CELZ survives, it's going to be a force to be reckoned with. Hang on to sound reasoning in the interim now matter how desperate the PPS may get compared to last month (or dare I say spring). It really had no justification for being at 7 cents any more than it does to be at 3.4 cents. For "fair" to prevail, we need financials and guidance as FINS are the ethos of real valuation. Each 10q from here on should provide just that. Don't expect a grand slam for Q2 figures but it should stabilize things a bit. Q3 and 4 should really bolster the PPS if they keep up this pace of signing on docs and the kits get made and shipped out to all these global facilities. Q1/2 of 2019 will start the recurring revenue engines as actual procedures start to get done and documented in one form or fashion.
That's all for me for now. I truly mean it when I say, "red or green don't mean a thing until FINS come swimming in." But I'd be damned if I didn't say that I would prefer we hover around a nickel or a dime while we wait! Hang on for the haul and peace to you in the waiting. I am not selling and will NOT be selling any of my shares until this thing gets north of at least $0.25 - Starbeck
So now we're "hoping" a chart is right but whether it is or isn't depends on the hard 10Q facts (i.e. fundamentals?). Hoping in charts is right up there with praying for news...it's all winging it! If charts need news to support their value then I'm afraid that tells you all you need to know about their credibility. Some guys may be nice and talk charts but that sure don't make it a safe "bet".
Buy the company on it's merits or run like the wind blows. JMHO.
And who here thinks they're getting better at it each and every time?
Count me in for sure...
I learned "What goes up...must come down..." But, has that happened with G00gLe or AMaz0n lately? I think G00gle dutch IPO'd around $88. They haven't been under $100 PPS in how many years?
SOmetimes stocks do defy the laws of physics and CELZ will be one of them.
If you wait long enough, you can carry water in a sieve. Just wait for it to freeze.
HODL true Longz. The bullet train will leave the station soon enough.
= ) It's too easy. Really...ya either got the kahunas or ya don't. YOu sir, do. That's pretty obvious!
Going to be a sweet next few weeks...
Keep the faith CELZr's!
Hey GM, we be sitting at par together with our locked shares! The 5.2's...5.2r's, 5.2Millies or maybe the 10.4 galore? Whatever floats the boat.
Ain't no amount of shaken that's going to loosen my shares from this star powered hand.
We may close GREEN today.
And I'm not one to make those types of calls...just has that feeling to it, you know what I mean? Big plunge with shock n awe and then the venomous bite that sends it right back up to where it "should" of been all day.
Rolling Stones be playing on my music box...TIME IS ON MY (LONGZ) SIDE. Yes it is!
Yep. They're gunning for 'em cause their short axx's are about to be smoked like POTN with a positive Canadian vote!
Reactiontime - I second CF's welcome!
You make some good observations re: company confidence and their ability to raise money. That said, I think you're missing a huge piece of the equation that is currently underway: licensing revenue. From their AUA conference alone, they have probably generated $500k or more in licensing fees from the Docs who want to get in on this procedure. The Russian deal could of been a $1M fee or more. We simply won't know until the FINS come out. So, if you look at their burn rate, the revenue from licensing alone will more than cover their ops in the short-term and then as an extension of the up-front licensing fees, the revenue from kits sold will absolutely cover the operating nut as well as start throwing off hay into the profits barn.
Don't be shaken by the low volume MM plays you see today and until the FINS come. They are sitting in a tough spot and it is to be expected that they will throw the gauntlet at us LONGZ who have more shares each than most of the trading vol totals per day here as of late.
LONG AND STRONG. $CELZ!
On very low volume. Not surprising IMHO.
Red or Green don't mean a thing until FINs swim in...
Bingo. Let them eat *#$R)
Tuesday will bring better news than any pumpkin pic ever would.
Shake! Rattle! Watch 'em roll!
Only a fool would let go at this hour...Tuesday (8/14) is literally around the corner.
Depends on how hot the shorts wanna get burned. Let 'em take it to sub-penny for all I care. Ain't budging but I am BUYING.
Engines on, check. Lights, check. Flip the switch! Time to ride!
Well, sh&t. Keys on my board stuck twice...
I was trying to say "They did. Called Caverstem." in response to CELZY mgmt "throwing us a bone."
This was my last post for the day folks...don't sweat the MM's! Stay clear headed and wait for the sun to shine once again. It surely will.
GO CELZ!
The did. Called Cavertem.
Red or Green don't mean a thing until the 10Q comes in.
They just shake, rattle and hoping to make weak heads roll. Steady yourselves!
Ain't getting a single one of my shares.
-->CELZ IS STRONG.
Bones vs Blubber -
WOuld you rather get your limp D fixed by stem cells derived from bones or blubber? Think about this; slowly for some of you.
OK, now, recognize that CELZ has a patent on using the BONE marrow stem cells that actually nets Bone-rs with 90% efficacy per Dr. Gershman. Surely he wouldn't fib about such nonsense and lose his highly respected decades long career treating some of Hollywood's finest. Who is that stupid? A world renowned MD with the rich n famous clients to prove it? Me thinks not. The other stem cell derived ED treatments of yesteryear are fat derived stem cells and much like the old saying "ya ar whatcha eat", your woody is only gonna be as stiff as the goose doin the goosin'. My poetic license notwithstanding, CELZ is lightyears ahead of the sketchy stem cell ED procedures that have been around for some time. And, if any of you have dealt with FDA before (I have for many years) you would know that if they don't require something by their own CFR (code of federal regulations) they aren't just going to suddenly change it and demand compliance. Ain't the way it works folks. Think tons of red tape and YEARS to get anything changed for better or worse. CELZ has a hall pass by FDA's own issued CFR. That's worth it's weight in GOLD or in this case USD.
Good things come to those who wait. In this case, it goes for woody's too.
CMTH is LEGIT.
An old goad for us rock solid Longz:
- First they ignore you
- Then they laugh at you
- THen they fight you
- Then you WIN.
CELZ will not only make old wieners winners, but they will also make those already LONG winners too!
GO CELZY!!!
5.21M locked here...and counting!
Dr. Gershman is good enough for me. If you really haven't researched his history or his contributions both medically and also from a consulting perspective, you're wasting not only our time with your questions but your time as well.
People are sooooo lazy. Said with a Donald T via Steven Colbert imitation...
Tight and Caverstem'd go well together. ; P
It's totally understandable that you want play by plays, especially if you are in fact the largest shareholder on this board. That said, I have personally been connected with the ceo and cfo on LinkedIn and I'm comfortable with their reps being legit. If it is a big scam then I hope they run it high before it folds! It is otc and one must be wise that anything is possible (for the worse more than anything) but I do have real confidence in Celz in despite all the logical reasons to trust nothing in otc.
Good luck and hang strong Buillit!
I disagree with this sentiment. I don't think care whether they respond to me. That's not the way it works and frankly I hope they're working more productively than spending time answering penny stock owner questions. Maybe by the time they uplift to Nasdaq should they consider more transparency. Until then, let's all hope they spend every waking moment getting this thing off the ground.
No offense intended, just my few pennies worth of thoughts.
Long for the haul with mortgage sized position on the line.
Cheers!